+

WO2007005534A8 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
WO2007005534A8
WO2007005534A8 PCT/US2006/025402 US2006025402W WO2007005534A8 WO 2007005534 A8 WO2007005534 A8 WO 2007005534A8 US 2006025402 W US2006025402 W US 2006025402W WO 2007005534 A8 WO2007005534 A8 WO 2007005534A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
directed
ikk2
formula
treatment
Prior art date
Application number
PCT/US2006/025402
Other languages
French (fr)
Other versions
WO2007005534A2 (en
WO2007005534A3 (en
Inventor
Jianghe Deng
Jeffrey K Kerns
Qi Jin
Guoliang Lin
Xichen Lin
Michael Lindenmuth
Christopher E Neipp
Hong Nie
Sonia M Thomas
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Jianghe Deng
Jeffrey K Kerns
Qi Jin
Guoliang Lin
Xichen Lin
Michael Lindenmuth
Christopher E Neipp
Hong Nie
Sonia M Thomas
Katherine L Widdowson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2006800304481A priority Critical patent/CN101247804B/en
Priority to CA002613068A priority patent/CA2613068A1/en
Priority to EA200800183A priority patent/EA014083B1/en
Priority to JP2008519569A priority patent/JP5059756B2/en
Priority to MX2007016541A priority patent/MX2007016541A/en
Priority to EP06785861A priority patent/EP1896014A4/en
Priority to BRPI0611674-4A priority patent/BRPI0611674A2/en
Priority to AU2006266028A priority patent/AU2006266028B2/en
Priority to NZ563687A priority patent/NZ563687A/en
Application filed by Smithkline Beecham Corp, Jianghe Deng, Jeffrey K Kerns, Qi Jin, Guoliang Lin, Xichen Lin, Michael Lindenmuth, Christopher E Neipp, Hong Nie, Sonia M Thomas, Katherine L Widdowson filed Critical Smithkline Beecham Corp
Publication of WO2007005534A2 publication Critical patent/WO2007005534A2/en
Publication of WO2007005534A3 publication Critical patent/WO2007005534A3/en
Priority to ZA2007/09948A priority patent/ZA200709948B/en
Priority to IL187786A priority patent/IL187786A0/en
Publication of WO2007005534A8 publication Critical patent/WO2007005534A8/en
Priority to NO20080457A priority patent/NO20080457L/en
Priority to US13/273,408 priority patent/US8354406B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: Formula (I) where R1 , R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
PCT/US2006/025402 2005-06-30 2006-06-28 Chemical compounds WO2007005534A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ563687A NZ563687A (en) 2005-06-30 2006-06-28 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
EA200800183A EA014083B1 (en) 2005-06-30 2006-06-28 Novel indole carboxamide derivatives, a pharmaceutical composition comprising thereof and a method for treating thereof
JP2008519569A JP5059756B2 (en) 2005-06-30 2006-06-28 Compound
MX2007016541A MX2007016541A (en) 2005-06-30 2006-06-28 Chemical compounds.
EP06785861A EP1896014A4 (en) 2005-06-30 2006-06-28 Chemical compounds
BRPI0611674-4A BRPI0611674A2 (en) 2005-06-30 2006-06-28 chemical compounds
AU2006266028A AU2006266028B2 (en) 2005-06-30 2006-06-28 Chemical compounds
CN2006800304481A CN101247804B (en) 2005-06-30 2006-06-28 Chemical compounds
CA002613068A CA2613068A1 (en) 2005-06-30 2006-06-28 Indole carboxamides as ikk2 inhibitors
ZA2007/09948A ZA200709948B (en) 2005-06-30 2007-11-19 Chemical Compounds
IL187786A IL187786A0 (en) 2005-06-30 2007-11-29 Chemical compounds
NO20080457A NO20080457L (en) 2005-06-30 2008-01-24 Chemical connections
US13/273,408 US8354406B2 (en) 2005-06-30 2011-10-14 Chemical compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69525605P 2005-06-30 2005-06-30
US60/695,256 2005-06-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11931189 A-371-Of-International 2006-06-28
US13/273,408 Division US8354406B2 (en) 2005-06-30 2011-10-14 Chemical compounds

Publications (3)

Publication Number Publication Date
WO2007005534A2 WO2007005534A2 (en) 2007-01-11
WO2007005534A3 WO2007005534A3 (en) 2007-04-26
WO2007005534A8 true WO2007005534A8 (en) 2008-01-17

Family

ID=37605008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025402 WO2007005534A2 (en) 2005-06-30 2006-06-28 Chemical compounds

Country Status (19)

Country Link
EP (1) EP1896014A4 (en)
JP (1) JP5059756B2 (en)
KR (1) KR20080021077A (en)
CN (1) CN101247804B (en)
AR (1) AR055343A1 (en)
AU (1) AU2006266028B2 (en)
BR (1) BRPI0611674A2 (en)
CA (1) CA2613068A1 (en)
EA (1) EA014083B1 (en)
IL (1) IL187786A0 (en)
MA (1) MA29566B1 (en)
MX (1) MX2007016541A (en)
NO (1) NO20080457L (en)
NZ (1) NZ563687A (en)
PE (1) PE20070173A1 (en)
TW (1) TWI380973B (en)
UA (1) UA99699C2 (en)
WO (1) WO2007005534A2 (en)
ZA (1) ZA200709948B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
PE20060748A1 (en) * 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2
GB0525164D0 (en) * 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US20080293802A1 (en) * 2005-12-16 2008-11-27 Smithline Beecham Corporation Chemical Compounds
PE20081889A1 (en) 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
ES2490867T3 (en) * 2008-12-19 2014-09-04 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
WO2010102968A1 (en) * 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
MX355943B (en) * 2013-06-26 2018-05-07 Abbvie Inc Primary carboxamides as btk inhibitors.
SG10201903578VA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022581A (en) * 1997-08-06 2001-03-26 피터 지. 스트링거 2-Acylaminopropanamines as Tachykinin Receptor Antagonists
DE19807993A1 (en) 1998-02-26 1999-09-02 Bayer Ag Treating tumor necrosis factor mediated inflammatory disease, e.g. arteriosclerosis, using new or known beta-carboline derivatives
DE19928424A1 (en) 1999-06-23 2000-12-28 Aventis Pharma Gmbh New aminoacid residue substituted benzimidazole derivative I(kappa)B-kinase inhibitors, useful for treating NF(kappa)B-related disorders e.g. rheumatoid arthritis, asthma, Alzheimer's disease and cancer
KR100718830B1 (en) 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 Substituted benzimidazole and preparation method thereof
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
EP1209158A1 (en) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substituted beta-carbolines
JP2001278886A (en) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd Benzoxazine derivative and medicament containing the same
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP4272338B2 (en) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
US6960585B2 (en) 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
WO2002030423A1 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
WO2002030353A2 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
AU3980602A (en) 2000-10-26 2002-06-03 Tularik Inc Antiinflammation agents
JP2002193938A (en) 2000-12-01 2002-07-10 Bayer Ag 4-arylpyridine derivative
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1363993A4 (en) 2001-02-01 2008-11-12 Bristol Myers Squibb Co METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
ATE442362T1 (en) 2001-05-24 2009-09-15 Leo Pharma As PYRIDYLCYANOGUANIDINE COMPOUNDS
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
US6638679B2 (en) 2001-07-12 2003-10-28 Kodak Polychrome Graphics, Llc Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6956052B2 (en) 2001-09-19 2005-10-18 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
EP1438293A2 (en) 2001-09-19 2004-07-21 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2003035625A1 (en) 2001-09-19 2003-05-01 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
BR0213734A (en) 2001-10-30 2004-10-19 Pharmacia Corp Heteroaromatic carboxamide derivatives for the treatment of inflammation
WO2003084959A1 (en) 2002-04-03 2003-10-16 Bristol-Myers Squibb Company Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
AU2003220483A1 (en) 2002-05-09 2003-11-11 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
PL373424A1 (en) 2002-06-06 2005-08-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
DE60334386D1 (en) * 2002-08-09 2010-11-11 Merck Sharp & Dohme tyrosine kinase inhibitors
DE10237722A1 (en) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
WO2004075846A2 (en) 2003-02-25 2004-09-10 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
EP1651629A1 (en) 2003-07-31 2006-05-03 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzothiophene compounds and uses thereof
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
MXPA06003746A (en) 2003-10-14 2006-06-14 Pharmacia Corp Substituted pyrazinone compounds for the treatment of inflammation.
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (en) * 2004-06-24 2006-10-11 Smithkline Beecham Corp COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
CN101060842A (en) * 2004-09-21 2007-10-24 葛兰素集团有限公司 Chemical compounds
PE20060748A1 (en) * 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2

Also Published As

Publication number Publication date
EP1896014A2 (en) 2008-03-12
AU2006266028A1 (en) 2007-01-11
EP1896014A4 (en) 2010-07-21
NZ563687A (en) 2011-07-29
MX2007016541A (en) 2008-03-07
PE20070173A1 (en) 2007-03-14
ZA200709948B (en) 2009-03-25
BRPI0611674A2 (en) 2009-04-28
TWI380973B (en) 2013-01-01
KR20080021077A (en) 2008-03-06
AR055343A1 (en) 2007-08-22
WO2007005534A2 (en) 2007-01-11
CN101247804B (en) 2012-09-26
UA99699C2 (en) 2012-09-25
CN101247804A (en) 2008-08-20
CA2613068A1 (en) 2007-01-11
EA014083B1 (en) 2010-08-30
IL187786A0 (en) 2008-08-07
NO20080457L (en) 2008-01-29
TW200738588A (en) 2007-10-16
JP2009500338A (en) 2009-01-08
AU2006266028B2 (en) 2012-03-15
JP5059756B2 (en) 2012-10-31
WO2007005534A3 (en) 2007-04-26
EA200800183A1 (en) 2008-08-29
MA29566B1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
WO2006034317A3 (en) Chemical compounds
WO2007076286A3 (en) Chemical compounds
WO2007005534A3 (en) Chemical compounds
MX2009010270A (en) Indole carboxamides as ikk2 inhibitors.
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
WO2006002434A3 (en) Novel indazole carboxamides and their use
WO2007114848A3 (en) Chemical compounds
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
WO2007102883A3 (en) Chemical compounds
WO2010018109A3 (en) Substituted aminotetralines
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2010018113A3 (en) Bi-aryl aminotetralines
WO2007062318A3 (en) Chemical compounds
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
NZ591426A (en) P38 map kinase inhibitors
WO2009023539A3 (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2010018112A3 (en) Monoaryl aminotetralines
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
WO2006110173A3 (en) Novel compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680030448.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12007502622

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 563687

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 187786

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 9298/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006785861

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 07132380

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016541

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2613068

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008519569

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077030656

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006266028

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2008000045

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200800183

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a200714940

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2006266028

Country of ref document: AU

Date of ref document: 20060628

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0611674

Country of ref document: BR

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载